![]() |
Home
Search
Study Topics
Glossary
|
Descriptive Information Fields | |||||||||
---|---|---|---|---|---|---|---|---|---|
Brief Title † | A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) | ||||||||
Official Title † | A Prospective, Multicenter, Phase II/III, Open-Label, Controlled, Randomized Trial Evaluating the Efficacy, Safety, and Tolerability of Interferon-Alfa-2a Plus Ribavirin Versus PEG-Interferon-Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus (HCV) Infection in Individuals Co-Infected With Human Immunodeficiency Virus-1 (HIV-1) | ||||||||
Brief Summary | The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than interferon-alfa-2a (IFN) plus ribavirin for patients infected with both HCV and HIV. The study will also compare the 2 regimens to see which has fewer side effects. HCV infection is common in patients infected with HIV. Patients infected with both HIV and HCV viruses seem to have more severe hepatitis C. A combination of IFN and ribavirin has been shown to lessen the severity of HCV. PEG-IFN is a modified form of IFN that stays in the blood longer, which means that patients would not have to take the treatment as often. This study will compare the safety and effectiveness of PEG-IFN to IFN when each is combined with ribavirin. |
||||||||
Detailed Description | Infection with HCV is common in patients infected with HIV owing to similar routes of transmission. The cellular immunosuppression caused by HIV infection appears to lead to an increased HCV plasma load, more progressive liver disease, and, in patients with chronic hepatitis C, increased mortality. Ribavirin treatment combined with IFN has shown improved sustained virologic response rates over IFN monotherapy. PEG-IFN, a chemically modified formulation of IFN, circulates for a much longer time in the blood than the parent compound. Pharmacokinetic and pharmacodynamic data suggest that PEG-IFN injected weekly would have the potential for superior efficacy as compared with IFN injected 3 times per week. The efficacy and safety profiles of combination therapy with PEG-IFN and ribavirin are not well known. This study will compare combination therapy consisting of PEG-IFN and ribavirin with that of IFN and ribavirin. Patients are stratified according to HCV genotype and CD4 count and viral load, then randomized to either Arm A (IFN plus ribavirin) or Arm B (PEG-IFN plus ribavirin). Patients receive up to 48 weeks of treatment. Virologic response is assessed at Week 24 and a decision to continue or discontinue treatment is made. If a virologic response is shown at Week 24, the patient continues treatment for an additional 24 weeks. If no virologic response is observed, then the histologic response is assessed by a liver biopsy. If biopsy shows a histologic response is present, treatment is continued for 24 weeks. If biopsy shows no histologic response, treatment is discontinued. [AS PER AMENDMENT 07/20/01: Patients with virologic response who discontinue after Week 24 will have liver biopsy at time of discontinuation. Patients with no virologic response continuing study treatment after having a liver biopsy within 2 weeks of Week 24, who also demonstrate histologic response and decide to discontinue after Week 24, are strongly encouraged to have a 2nd liver biopsy at the end of treatment. Patients with no virologic response who discontinue after Week 24 will not have liver biopsy at time of discontinuation.] Physical examinations are done regularly and blood samples collected for routine laboratory tests, confidential genetic testing, and to measure HCV and HIV-1 plasma viral loads. Women able to become pregnant have regular pregnancy tests. All patients are followed for an additional 24 weeks after treatment discontinuation. Patients may enroll in 1 or none of the following substudies: A5091s, Hepatic C Viral Kinetics in Subjects Co-infected with Human Immunodeficiency Virus-1 (HIV-1) and Hepatitis C Virus Genotype 1 (HCV-1); [AS PER AMENDMENT 07/20/01: The following text has been deleted: or A5092s, Evaluation of the Effects of Ribavirin on Zidovudine (ZDV) or Stavudine (d4T) Triphosphate Formation] [AS PER AMENDMENT 07/20/01: Substudy A5092s, Evaluation of the Effects of Ribavirin on Zidovudine (ZDV) or Stavudine (d4T) Triphosphate Formation is now a stand-alone study.] |
||||||||
Study Phase | Phase II | ||||||||
Study Type † | Interventional | ||||||||
Study Design † | Treatment, Safety Study | ||||||||
Primary Outcome Measure † | |||||||||
Secondary Outcome Measure † | |||||||||
Condition † | HIV Infections Hepatitis C |
||||||||
Intervention † | Drug: Ribavirin Drug: Interferon alfa-2a Drug: Peginterferon alfa-2a |
||||||||
MEDLINE PMIDs | 15282352, 15563253, 15685543, 15867490, 16115185, 16439867 | ||||||||
Links | Click here for more information about interferon alfa-2 ![]() Click here for more information about peginterferon alfa-2a  ![]() Click here for more information about ribavirin  ![]() Haga clic aquí para ver información sobre este ensayo clínico en español.  ![]() |
||||||||
Recruitment Information Fields | |||||||||
Recruitment Status † | Completed | ||||||||
Enrollment † | 132 | ||||||||
Start Date † | |||||||||
Completion Date | August 2006 | ||||||||
Eligibility Criteria † | Inclusion Criteria Patients may be eligible for this study if they:
Exclusion Criteria Patients will not be eligible for this study if they:
|
||||||||
Gender | Both | ||||||||
Ages | 18 Years to 65 Years | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts †† | |||||||||
Location Countries † | United States | ||||||||
Administrative Information Fields | |||||||||
NCT ID † | NCT00008463 | ||||||||
Organization ID | ACTG A5071 | ||||||||
Secondary IDs †† | AACTG A5071, Substudy AACTG A5091s | ||||||||
Study Sponsor † | National Institute of Allergy and Infectious Diseases (NIAID) | ||||||||
Collaborators †† | |||||||||
Investigators † |
|
||||||||
Information Provided By | National Institute of Allergy and Infectious Diseases (NIAID) | ||||||||
Verification Date | May 2005 | ||||||||
First Received Date † | January 9, 2001 | ||||||||
Last Updated Date | December 19, 2008 |